https://www. theguardian.com/media/2026/aug /22/deadly-tiktok-motorway-driving-trend-horrifies-ireland
https://www.
mastodon:mstdn-social 34d ago
https://www.
The FDA approved Revolution Medicines' daraxonrasib on August 26–27, 2026, a landmark pancreatic cancer treatment that nearly doubled average survival times in trials; the drug is priced above $475,000 annually.
Revolution Medicines received FDA approval on August 26, 2026, for daraxonrasib (Rasonque), a once-daily pill that blocks RAS protein variants driving pancreatic cancer growth.
The Food and Drug Administration approved Rasonque (daraxonrasib), a once-daily targeted therapy by Revolution Medicines, on August 26, 2026 for adults with metastatic pancreatic adenocarcinoma. The drug represents the first in its class for this indication.